A Meta-analysis of D-cycloserine and the Facilitation of Fear Extinction and Exposure Therapy

[1]  A. Guastella,et al.  A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder , 2008, Biological Psychiatry.

[2]  S. Rauch,et al.  Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. , 2008, The American journal of psychiatry.

[3]  R. Richardson,et al.  Effects of D-Cycloserine on Extinction: Consequences of Prior Exposure to Imipramine , 2007, Biological Psychiatry.

[4]  J. Krystal.  Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy , 2007, Biological Psychiatry.

[5]  Christopher B. Donahue,et al.  D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder , 2007, Biological Psychiatry.

[6]  A. Guastella,et al.  A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. , 2007, Journal of psychiatric research.

[7]  Stefan G Hofmann,et al.  Enhancing exposure-based therapy from a translational research perspective. , 2007, Behaviour research and therapy.

[8]  Danielle M. Williams,et al.  D-cycloserine Inhibits Amygdala Responses During Repeated Presentations of Faces , 2007, CNS Spectrums.

[9]  E. Storch,et al.  D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder , 2007, International clinical psychopharmacology.

[10]  M. Packard,et al.  D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction. , 2007, Learning & memory.

[11]  N. Dubrovina,et al.  Effects of activation and blockade of NMDA receptors on the extinction of a conditioned passive avoidance response in mice with different levels of anxiety , 2007, Neuroscience and Behavioral Physiology.

[12]  Y. Itzhak,et al.  Long-term memory of cocaine-associated context: disruption and reinstatement , 2007, Neuroreport.

[13]  A. Lingford-Hughes,et al.  d-Cycloserine and performance under different states of anxiety in healthy volunteers , 2007, Psychopharmacology.

[14]  K. Lu,et al.  Glutamate NMDA Receptors within the Amygdala Participate in the Modulatory Effect of Glucocorticoids on Extinction of Conditioned Fear in Rats , 2007, Neuropsychopharmacology.

[15]  R. Richardson,et al.  Effects of d-cycloserine on extinction of learned fear to an olfactory cue , 2007, Neurobiology of Learning and Memory.

[16]  A. Guastella,et al.  A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. , 2007, Behaviour research and therapy.

[17]  I. Akirav.  NMDA Partial Agonist Reverses Blocking of Extinction of Aversive Memory by GABAA Agonist in the Amygdala , 2007, Neuropsychopharmacology.

[18]  S. Hofmann,et al.  Clinical Perspectives on the Combination of D-Cycloserine and Cognitive-Behavioral Therapy for the Treatment of Anxiety Disorders , 2007, CNS Spectrums.

[19]  R. Oosting,et al.  Delay aversion: Effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and d-cycloserine , 2006, Pharmacology Biochemistry and Behavior.

[20]  V. Molina,et al.  Influence of ethanol withdrawal on fear memory: Effect of d-cycloserine , 2006, Neuroscience.

[21]  Michael Davis,et al.  Neural systems involved in fear and anxiety measured with fear-potentiated startle. , 2006, The American psychologist.

[22]  D. Charney,et al.  Neurobiology of anxiety disorders and implications for treatment. , 2006, The Mount Sinai journal of medicine, New York.

[23]  M. Bouton,et al.  D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. , 2006, Behavioral neuroscience.

[24]  B. Everitt,et al.  Reconsolidation and Extinction of Conditioned Fear: Inhibition and Potentiation , 2006, The Journal of Neuroscience.

[25]  J. Stewart,et al.  d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference , 2006, Behavioural Brain Research.

[26]  S. Hofmann,et al.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. , 2006, CNS drug reviews.

[27]  P. Gean,et al.  Extinction Training in Conjunction with a Partial Agonist of the Glycine Site on the NMDA Receptor Erases Memory Trace , 2006, The Journal of Neuroscience.

[28]  Rick Richardson,et al.  Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work , 2006, Biological Psychiatry.

[29]  Richard Coppola,et al.  The G72/G30 Gene Complex and Cognitive Abnormalities in Schizophrenia , 2006, Neuropsychopharmacology.

[30]  Naomi M Simon,et al.  Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. , 2006, Archives of general psychiatry.

[31]  J. Krystal,et al.  First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.

[32]  M. Kozak,et al.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. , 2007, The American journal of psychiatry.

[33]  Yi Ling Yang,et al.  Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala , 2005, Neuroscience.

[34]  Chih-Chiang Chiu,et al.  Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. , 2005, Archives of general psychiatry.

[35]  K. Ressler,et al.  Emotional Learning and Glutamate: Translational Perspectives , 2005, CNS Spectrums.

[36]  E. Foa,et al.  Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: outcome at academic and community clinics. , 2005, Journal of consulting and clinical psychology.

[37]  Michael Davis,et al.  Facilitation of Extinction of Conditioned Fear by D-Cycloserine , 2005 .

[38]  R. Richardson,et al.  Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats , 2005, Neurobiology of Learning and Memory.

[39]  R. Richardson,et al.  d-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction , 2005, Biological Psychiatry.

[40]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.

[41]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[42]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[43]  J. Corwin,et al.  Effects of d-cycloserine on negative symptoms in schizophrenia , 2004, Schizophrenia Research.

[44]  Barbara O Rothbaum,et al.  Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. , 2004, Archives of general psychiatry.

[45]  A. Bordey,et al.  Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices , 2004, The Journal of physiology.

[46]  K. Gadde,et al.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. , 2004, Archives of general psychiatry.

[47]  R. Richardson,et al.  Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. , 2004, Learning & memory.

[48]  L. Birk.  Pharmacotherapy for performance anxiety disorders: occasionally useful but typically contraindicated. , 2004, Journal of clinical psychology.

[49]  S. B. Caine,et al.  Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Richardson,et al.  D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. , 2004, Behavioral neuroscience.

[51]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[52]  R. Schiffmann,et al.  White matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions , 2003, Brain Research Bulletin.

[53]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[54]  P. Mallorga,et al.  The Glycine Transporter Type 1 Inhibitor N-[3-(4′-Fluorophenyl)-3-(4′-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior , 2003, The Journal of Neuroscience.

[55]  Michael Davis,et al.  Role of the Amygdala in Fear Extinction Measured with Potentiated Startle , 2003, Annals of the New York Academy of Sciences.

[56]  R. Richardson,et al.  Effects of D-cycloserine on extinction of conditioned freezing. , 2003, Behavioral neuroscience.

[57]  W. Ju,et al.  Glycine binding primes NMDA receptor internalization , 2003, Nature.

[58]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[59]  R. Reep,et al.  Effects of light deprivation on recovery from neglect and extinction induced by unilateral lesions of the medial agranular cortex and dorsocentral striatum , 2003, Behavioural Brain Research.

[60]  S. Royer,et al.  Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses , 2002, Neuroscience.

[61]  R. Reep,et al.  Unilateral destruction of the dorsocentral striatum in rats produces neglect but not extinction to bilateral simultaneous stimulation , 2002, Behavioural Brain Research.

[62]  Michael Davis,et al.  Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy * , 2002, The European journal of neuroscience.

[63]  K. Laake,et al.  D-cycloserine for Alzheimer's disease. , 2002, The Cochrane database of systematic reviews.

[64]  Michael Davis,et al.  Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of d-Cycloserine as Assessed with Fear-Potentiated Startle in Rats , 2002, The Journal of Neuroscience.

[65]  Stephen Maren,et al.  Long‐term potentiation as a substrate for memory: Evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning , 2002, Hippocampus.

[66]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.

[67]  R. Muller,et al.  Consolidation of Extinction Learning Involves Transfer from NMDA-Independent to NMDA-Dependent Memory , 2001, The Journal of Neuroscience.

[68]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[69]  A. Le Goff,et al.  The Glial and the Neuronal Glycine Transporters Differ in Their Reactivity to Sulfhydryl Reagents* , 2001, The Journal of Biological Chemistry.

[70]  M K Shear,et al.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. , 2000, JAMA.

[71]  J. Krystal,et al.  IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans , 2000, Biological Psychiatry.

[72]  J. Olney,et al.  Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and α2-adrenergic agonists , 1999, Molecular Psychiatry.

[73]  Joseph E LeDoux,et al.  Why We Think Plasticity Underlying Pavlovian Fear Conditioning Occurs in the Basolateral Amygdala , 1999, Neuron.

[74]  J. Coyle,et al.  Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. , 1999, The American journal of psychiatry.

[75]  R G Shulman,et al.  Energy on Demand , 1999, Science.

[76]  M. Liebowitz,et al.  Psychometric properties of the Liebowitz Social Anxiety Scale , 1999, Psychological Medicine.

[77]  J. Coyle,et al.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. , 1999, Archives of general psychiatry.

[78]  J. Coyle,et al.  Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[80]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[81]  R. Nicoll,et al.  Postsynaptically Silent Synapses in Single Neuron Cultures , 1998, Neuron.

[82]  R. Port,et al.  Manipulation of NMDA-receptor activity alters extinction of an instrumental response in rats , 1998, Physiology & Behavior.

[83]  R. Mattick,et al.  Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. , 1998, Behaviour research and therapy.

[84]  J. Krystal,et al.  601 Glycine ketamine interactions in healthy humans , 1997, Schizophrenia Research.

[85]  Joseph E LeDoux,et al.  Fear conditioning induces associative long-term potentiation in the amygdala , 1997, Nature.

[86]  M K Shear,et al.  Multicenter collaborative panic disorder severity scale. , 1997, The American journal of psychiatry.

[87]  T. Kikuchi,et al.  Effects of ketamine and pentobarbitone on acetylcholine release from the rat frontal cortex in vivo. , 1997, British journal of anaesthesia.

[88]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[89]  K. L. Leenders,et al.  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) , 1997, European Neuropsychopharmacology.

[90]  A. Malhotra,et al.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. , 1997, The American journal of psychiatry.

[91]  D. Goebel.  Quantitative gene expression of two types of glycine transporter in the rat central nervous system. , 1996, Brain research. Molecular brain research.

[92]  F. Jursky,et al.  Developmental Expression of the Glycine Transporters GLYT1 and GLYT2 in Mouse Brain , 1996, Journal of neurochemistry.

[93]  J. Azorlosa,et al.  The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. , 1996, Behavioral Neuroscience.

[94]  M. Hasselmo,et al.  NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[95]  T. Brown,et al.  Long-term outcome in cognitive-behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. , 1995, Journal of consulting and clinical psychology.

[96]  R. Herting,et al.  Evaluation of Cycloserine in the Treatment of Alzheimer's Disease , 1995, Journal of geriatric psychiatry and neurology.

[97]  J. Krystal,et al.  Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .

[98]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[99]  J. Storm-Mathisen,et al.  Glycine transporters are differentially expressed among CNS cells , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[100]  M. Tohyama,et al.  Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[101]  P. Salkovskis,et al.  A Comparison of Cognitive Therapy, Applied Relaxation and Imipramine in the Treatment of Panic Disorder , 1994, British Journal of Psychiatry.

[102]  R. F. Westbrook,et al.  The NMDA Receptor Antagonist MK-801 Blocks Acquisition and Extinction of Conditioned Hypoalgesic Responses in the Rat , 1994, The Quarterly journal of experimental psychology. B, Comparative and physiological psychology.

[103]  Suck-Won Kim,et al.  The Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency , 1994, Psychiatry Research.

[104]  C. Randolph,et al.  D‐Cycloserine Treatment of Alzheimer Disease , 1994, Alzheimer disease and associated disorders.

[105]  P. Lelliott,et al.  Alprazolam and Exposure Alone and Combined in Panic Disorder with Agoraphobia , 1993, British Journal of Psychiatry.

[106]  B. Borowsky,et al.  Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene , 1993, Neuron.

[107]  P. Skolnick,et al.  Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures , 1993, Brain Research.

[108]  D H Barlow,et al.  Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up. , 1993, Behaviour research and therapy.

[109]  J. Kemp,et al.  The glycine site of the NMDA receptor--five years on. , 1993, Trends in pharmacological sciences.

[110]  P. Wisocki.  The practice of behavior therapy , 1992 .

[111]  P. Wood,et al.  Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo , 1991, Neuropharmacology.

[112]  M. Bolanowski,et al.  d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed inXenopus oocytes , 1990, Brain Research.

[113]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.

[114]  J. Monahan,et al.  d-Cycloserine: A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics , 1989, Neuroscience Letters.

[115]  David H. Barlow,et al.  Psychological treatment of panic , 1988 .

[116]  R. Rosenthal.  Meta-analytic procedures for social research , 1984 .

[117]  G. Glass,et al.  Meta-analysis in social research , 1981 .

[118]  Joseph Wolpe,et al.  The practice of behavior therapy, 2nd ed. , 1973 .